At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
ABCL AbCellera Biologics
Market Closed 08-28 16:00:00 EDT
11.35
-1.05
-8.47%
盘后11.34
-0.01-0.11%
19:59 EDT
High12.35Low11.26Vol5.86M
Open12.31D1 Closing12.40Amplitude8.79%
Mkt Cap3.68BTradable Cap2.51BTotal Shares324.00M
T/O67.83MT/O Rate2.65%Tradable Shares221.00M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Movement Alert｜AbCellera Biologics Falls 8.02% in Regular Trading, Life Sciences Sector Broadly Under Pressure Post Dilutive Offering
Market Focus  ·  08-29 00:30
Movement Alert｜AbCellera Biologics Falls 8.02% in Regular Trading, Life Sciences Sector Broadly Under Pressure Post Dilutive Offering
U.S. Small Caps Finish Mixed as AbCellera Biologics Leads, Bath & Body Works Lags
Dow Jones  ·  08-26
U.S. Small Caps Finish Mixed as AbCellera Biologics Leads, Bath & Body Works Lags
AbCellera rises 17.0%
TIPRANKS  ·  08-26
AbCellera rises 17.0%
Major Insider Move Signals Growing Confidence in AbCellera Biologics
TIPRANKS  ·  08-25
Major Insider Move Signals Growing Confidence in AbCellera Biologics
Abcellera Director Michael R. Hayden Reports $570,442 Common Share Purchase
Reuters  ·  08-25
Abcellera Director Michael R. Hayden Reports $570,442 Common Share Purchase
AbCellera Biologics call volume above normal and directionally bullish
TIPRANKS  ·  08-20
AbCellera Biologics call volume above normal and directionally bullish
Insider Confidence Surge: Director Makes Bold Move on AbCellera Biologics
TIPRANKS  ·  08-19
Insider Confidence Surge: Director Makes Bold Move on AbCellera Biologics
Abcellera Director John S. Montalbano Acquires Common Shares Worth $110,300
Reuters  ·  08-19
Abcellera Director John S. Montalbano Acquires Common Shares Worth $110,300
AbCellera Biologics (ABCL) Gets a Buy from BMO Capital
TIPRANKS  ·  08-18
AbCellera Biologics (ABCL) Gets a Buy from BMO Capital
Abcellera Director Michael R Hayden Reports Purchase of Common Shares Worth $481,234.19
Reuters  ·  08-14
Abcellera Director Michael R Hayden Reports Purchase of Common Shares Worth $481,234.19
U.S. Stocks on the MOVE-EnerSys, Netflix, Salesforce
Reuters  ·  08-14
U.S. Stocks on the MOVE-EnerSys, Netflix, Salesforce
AbCellera Dips After $200 Mln Share Sale for Menopause Drug
Reuters  ·  08-13
AbCellera Dips After $200 Mln Share Sale for Menopause Drug
AbCellera Announces Pricing of Oversubscribed $200 Million Public Offering of Common Shares
Reuters  ·  08-13
AbCellera Announces Pricing of Oversubscribed $200 Million Public Offering of Common Shares
AbCellera Prices Oversubscribed Public Offering at USD 9.75 Per Share to Raise USD 200 Million
Reuters  ·  08-13
AbCellera Prices Oversubscribed Public Offering at USD 9.75 Per Share to Raise USD 200 Million
Abcellera Announces Pricing of Oversubscribed $200 Million Public Offering of Common Shares and Pre-Funded Warrants
THOMSON REUTERS  ·  08-13
Abcellera Announces Pricing of Oversubscribed $200 Million Public Offering of Common Shares and Pre-Funded Warrants
Abcellera Biologics Inc.: Pricing of Public Offering of 17,435,897 Shares at a Price of $9.75 Per Share
THOMSON REUTERS  ·  08-13
Abcellera Biologics Inc.: Pricing of Public Offering of 17,435,897 Shares at a Price of $9.75 Per Share
Shares of Abcellera Biologics Down 7.9% Premarket After Launching $200 Mln Stock Offering
THOMSON REUTERS  ·  08-12
Shares of Abcellera Biologics Down 7.9% Premarket After Launching $200 Mln Stock Offering
AbCellera Biologics (ABCL) On ABCL635 Trial Results And A Richer Valuation Story
Simply Wall St.  ·  08-12
AbCellera Biologics (ABCL) On ABCL635 Trial Results And A Richer Valuation Story
AbCellera Biologics Launches $200 Million Public Offering
MT Newswires Live  ·  08-12
AbCellera Biologics Launches $200 Million Public Offering
Canada's Eupraxia Q2 Net Loss Widens on Higher R&D Costs
Reuters  ·  08-12
Canada's Eupraxia Q2 Net Loss Widens on Higher R&D Costs

Introduction

Company Name.
AbCellera Biologics
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
AbCellera Biologics Inc. builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company had discovery programs that are either completed, in progress, or under contract with partners. It has a research collaboration and license agreement with Eli Lilly and Company; and a research collaboration with Confo Therapeutics for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.
Issue price:
--